AAV‐delivered diacylglycerol kinase DGKk achieves long‐term rescue of fragile X syndrome mouse model - Archive ouverte HAL
Article Dans Une Revue EMBO Molecular Medicine Année : 2022

AAV‐delivered diacylglycerol kinase DGKk achieves long‐term rescue of fragile X syndrome mouse model

Résumé

Fragile X syndrome (FXS) is the most frequent form of familial intellectual disability. FXS results from the lack of the RNA-binding protein FMRP and is associated with the deregulation of signaling pathways downstream of mGluRI receptors and upstream of mRNA translation. We previously found that diacylglycerol kinase kappa (DGKk), a main mRNA target of FMRP in cortical neurons and a master regulator of lipid signaling, is downregulated in the absence of FMRP in the brain of Fmr1-KO mouse model. Here we show that adeno-associated viral vector delivery of a modified and FMRP-independent form of DGKk corrects abnormal cerebral diacylglycerol/phosphatidic acid homeostasis and FXS-relevant behavioral phenotypes in the Fmr1-KO mouse. Our data suggest that DGKk is an important factor in FXS pathogenesis and provide preclinical proof of concept that its replacement could be a viable therapeutic strategy in FXS.
Fichier principal
Vignette du fichier
2022 EMBO Mol Med - Habbas - AAV%u2010delivered diacylglycerol kinase DGKk achieves long%u2010term rescue of fragile X syndrome.pdf (1.23 Mo) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03710651 , version 1 (29-11-2021)
hal-03710651 , version 2 (25-11-2022)

Identifiants

Citer

Karima Habbas, Oktay Cakil, Boglárka Zámbó, Ricardos Tabet, Fabrice Riet, et al.. AAV‐delivered diacylglycerol kinase DGKk achieves long‐term rescue of fragile X syndrome mouse model. EMBO Molecular Medicine, 2022, 14 (5), ⟨10.15252/emmm.202114649⟩. ⟨hal-03710651v2⟩
133 Consultations
173 Téléchargements

Altmetric

Partager

More